The MarketReader Minute
π Humacyte Soars on License Deal, AbbVie Down with Regulatory Submissions, Biogen Drops Amid Market Competition | Biotech Sector Insights
Chief Medical Officer of Vertex Pharmaceuticals sold common shares on July 10th at $487.34 per share as disclosed in a regulatory filing. The Russell 2000 Index also moved up by 0.84%, which could be influencing IBB's movement given their historical correlation during today's pre-market session.